Orthocell Ltd · ASX:OCC
Orthocell — Euroz Hartleys Healthcare Forum 2023
20 slides from Orthocell's conference presentation, February 2023
Slide 1: Investor Presentation
Investor Presentation EUROZ HARTLEYS HEALTHCARE FORUM February 2023 1
Slide 2: Disclaimer
Disclaimer This presentation prepared by Orthocell Ltd (“Company”) does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or tr
Slide 3: Key investment highlights
Key investment highlights REGENERATING COMMERCIAL MANUFACTURING NEAR-TERM MOBILITY PARTNERS & PATENTS MILESTONES DELIVERING NOVEL GLOBAL LICENCE EXECUTED MANUFACTURING 1H CY2023 BIOLOGICAL PRODUCTS AND AUSTRALIAN FACILITY SCALE UP COMMERCIAL MILESTONES DISTRIBUTOR IN PLACE COMPLETE ✔ returning funct
Slide 4: Corporate snapshot
Corporate snapshot ASX: OCC TRADING INFORMATION SUBSTANTIAL SHAREHOLDERS Share Price 0.39 Shareholder % 12 month low/high $0.300/$0.580 Founders & Management 15.10% Shares outstanding 197,127,913 Institutions 4.5% Market Capitalisation 80M Cash (31 December) 26.81M With AU$26.81m cash at bank, OCC i
Slide 5: US strategic focus
US strategic focus Advanced product portfolio with near term milestones and emerging pipeline Clinical US Regulatory Phase Product Application Development Status (CY) Phase Design Trial Implement Trial Approved Engaged BioHorizons - exclusive license and Striate+ 1 manufacturing partner. Market laun
Slide 6: More than a barrier membrane
MORE THAN A BARRIER MEMBRANE 6
Slide 7: Striate+ premium dental membrane
Striate+ premium dental membrane ™ • Striate+ is a sterile, resorbable collagen membrane for use in dental bone and tissue regeneration procedures. • Striate+ is designed to protect the bone defect from ingrowth of gingival tissue, to provide a favourable environment for osteogenesis and to assure r
Slide 8: Striate+ global exclusive license and manufacturing agreement with BioHorizons
Striate+ global exclusive “ ™️ We are very pleased to partner with Orthocell license and manufacturing to offer our valued customers a dental membrane with excellent handling properties and regenerative potential. Striate+™️ will be agreement with BioHorizons a highly complementary addition to our g
Slide 9: Positioned for growth
Positioned for growth Unrestricted and non diluting capital • Non diluting payment is free of encumbrances - cash can be used without restrictions. Strong capital position • $26.81m cash at bank¹ • Well positioned to advance the commercialisation of the US nerve and tendon repair programs. Validatio
Slide 10: Striate+: path to partnering
Striate+ : path to partnering ™ Executed a strategy to engage a global partner to manage the distribution and marketing of Striate+ Clinical data and regulatory approval Successful regenerative medicine-driven product development strategy produced a market leading product approved in US, EU and AUS.
Slide 11: Revolutionising nerve repair
REVOLUTIONISING NERVE REPAIR 11
Slide 12: Traditional repair outcomes are suboptimal
Traditional repair outcomes are suboptimal Direct suture = tension, buckling and can be ineffective and unpredictable in restoring function. Normal Nerve Suture Remplir 12
Slide 13: Remplir – approved in Australia (TGA)
Remplir – approved in Australia (TGA) ™ Collagen nerve wrap intended for use in peripheral nerve repair GUIDING PREDICTABLE OUTCOMES IN PERIPHERAL NERVE REPAIR Exceptional handling characteristics Healing microenvironment Mimics epineurium (nerve outer layer) 13
Slide 14: Surgical technique – Remplir assisted coaptation
Surgical technique – Remplir assisted coaptation ™ 1 3 Wrapping Remplir around nerve ends to create Isolating a customised donor nerve conduit 2 4 Co-adapting Remplir guides donor and and supports recipient nerve nerve repair 14
Slide 15: Remplir: compelling long term clinical results
Remplir : compelling long term clinical results ™ “ We are now seeing a consistent return of arm and hand function following nerve transfer surgery with Remplir. Remplir is increasing the success rate and efficiency of nerve transfer surgery. Patients regained voluntary muscle movement - Leading Aus
Slide 16: Remplir case study
Remplir case study ™ “ The treatment I received to repair my nerve damage has been completely life-altering…I have now made a full recovery and am now able to compete tasks unassisted and pain-free giving me back my freedom and independence. Injury - Damien Hall, Remplir patient • Left hand injured
Slide 17: Remplir: Australian exclusive marketing and distribution partner
Remplir : Australian exclusive ™ marketing and distribution partner “ I am extremely excited to partner with Orthocell to bring their Australian made range of peripheral nerve repair membranes to plastic and orthopaedic surgeons around Australia. At Device Technologies AUS we believe in investing in
Slide 18: Valuation upside
Valuation upside Valuation comparison to other medical device and life science companies. Significant upside potential for OCC. Market Capitalisation $80m $320m $1.7B Company Medical device and autologous Device Autologous cell harvesting device Synthetic scaffold device injectable therapy Indicatio
Slide 19: Upcoming catalysts
Upcoming catalysts¹ Striate+™ premium periodontal membrane MDR CE Mark certification 1Q 2023 Academy of Osseointegration Annual Meeting EU & AU product launch 1H 2023 Remplir™ premium nerve wrap Australian Hand Surgery Society Annual Meeting US pre-clinical comparator study (510k) 1Q 2023 US KOL eng
Slide 20: Contact: Paul Anderson, Orthocell Limited
Co-Founder and Managing Director, Paul Anderson Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com 20